BiotechTube
Yarrow Bioscience

Yarrow Bioscience

YARW
San Diego, United States· Est.
yarrowbioscience.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $5M

Overview

Yarrow Bioscience's mission is to develop breakthrough antibody therapeutics for thyroid autoimmune diseases, starting with its lead candidate YB-101 targeting the thyroid-stimulating hormone receptor (TSHR). Its key achievement is securing a Nasdaq listing and approximately $200 million in financing through a strategic merger with VYNE Therapeutics, positioning it to fund operations into 2028. The company's strategy is highly focused, centering on the global ex-China development of YB-101, with planned Phase 1b/2b trials in Graves' disease and a parallel Phase 1 trial in thyroid eye disease conducted by its partner in China.

Autoimmune DiseasesEndocrinology

Technology Platform

The company's scientific foundation is a deep understanding of the thyroid-stimulating hormone receptor (TSHR), leveraged through its lead monoclonal antibody YB-101, a TSHR antagonist designed to treat Graves' disease and thyroid eye disease at their root cause.

Funding History

1
Total raised:$5M
Seed$5M

Opportunities

YB-101 addresses large, underserved markets in Graves' disease and Thyroid Eye Disease with a first-in-class, targeted mechanism.
The success of teprotumumab in TED validates the commercial potential for novel biologics in this space, and YB-101's dual-indication approach could unlock significant value.
Strong financial backing provides a long runway to reach key clinical data readouts without near-term dilution.

Risk Factors

The company is entirely dependent on the success of its single asset, YB-101, creating high binary risk.
It faces significant clinical development risk as a first-in-class therapy and must compete against an established, effective drug (teprotumumab) in the TED market.
Execution risk around the corporate merger and trial initiation is also present.

Competitive Landscape

In Graves' disease, YB-101 would be a first-in-class TSHR antagonist competing against non-targeted standard of care. In Thyroid Eye Disease, it faces direct competition from the blockbuster IGF-1R inhibitor teprotumumab, requiring demonstration of a superior or differentiated safety/efficacy profile through its more targeted mechanism.

More companies in Biologics / Biosimilars →More companies in United States →